Investors bought shares of Johnson & Johnson (NYSE:JNJ) on weakness during trading on Tuesday. $156.48 million flowed into the stock on the tick-up and $119.01 million flowed out of the stock on the tick-down, for a money net flow of $37.47 million into the stock. Of all stocks tracked, Johnson & Johnson had the 17th highest net in-flow for the day. Johnson & Johnson traded down ($0.59) for the day and closed at $132.27
Several brokerages have recently commented on JNJ. Jefferies Group LLC set a $145.00 target price on shares of Johnson & Johnson and gave the company a “hold” rating in a report on Tuesday. J P Morgan Chase & Co raised their price objective on shares of Johnson & Johnson from $140.00 to $148.00 and gave the stock an “overweight” rating in a report on Wednesday. Credit Suisse Group restated a “buy” rating on shares of Johnson & Johnson in a report on Friday, August 4th. Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Finally, Alembic Global Advisors downgraded shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a report on Friday, July 21st. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $134.12.
The company has a market cap of $355.98 billion, a price-to-earnings ratio of 22.44 and a beta of 0.78. The stock’s 50-day moving average price is $132.88 and its 200 day moving average price is $127.04.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The business had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. During the same quarter in the prior year, the company posted $1.74 EPS. The company’s quarterly revenue was up 1.9% on a year-over-year basis. On average, analysts predict that Johnson & Johnson will post $7.18 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.53%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 56.76%.
In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the sale, the vice president now owns 230,342 shares in the company, valued at approximately $30,667,733.88. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now owns 226,693 shares in the company, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.
Several hedge funds have recently made changes to their positions in JNJ. Lau Associates LLC boosted its stake in shares of Johnson & Johnson by 12.8% in the first quarter. Lau Associates LLC now owns 46,878 shares of the company’s stock worth $5,839,000 after buying an additional 5,335 shares during the period. Loomis Sayles & Co. L P boosted its stake in Johnson & Johnson by 396.7% in the fourth quarter. Loomis Sayles & Co. L P now owns 110,823 shares of the company’s stock worth $12,768,000 after buying an additional 88,510 shares during the last quarter. Jackson Grant Investment Advisers Inc. boosted its stake in Johnson & Johnson by 7.3% in the fourth quarter. Jackson Grant Investment Advisers Inc. now owns 14,124 shares of the company’s stock worth $1,627,000 after buying an additional 957 shares during the last quarter. Burke & Herbert Bank & Trust Co. boosted its stake in Johnson & Johnson by 2.6% in the first quarter. Burke & Herbert Bank & Trust Co. now owns 47,330 shares of the company’s stock worth $5,895,000 after buying an additional 1,218 shares during the last quarter. Finally, Independent Advisor Alliance bought a new stake in Johnson & Johnson during the fourth quarter worth $4,035,000. 66.10% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
